Cite
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
MLA
Löwenberg, Bob, et al. Addition of Lenalidomide to Intensive Treatment in Younger and Middle-Aged Adults with Newly Diagnosed AML: The HOVON-SAKK-132 Trial. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........f57abf9094f416349bbd7f9ecc75fc32&authtype=sso&custid=ns315887. Accessed 15 Sept. 2024.
APA
Löwenberg, B., Pabst, T., Maertens, J., Gradowska, P., Biemond, B. J., Spertini, O., Vellenga, E., Griskevicius, L., Tick, L. W., Jongen-Lavrencic, M., van Marwijk Kooy, M., Vekemans, M.-C., van der Velden, W. J. F. M., Beverloo, B., Michaux, L., Graux, C., Deeren, D., de Weerdt, O., van Esser, J. W. J., … Ossenkoppele, G. J. (n.d.). Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial.
Chicago
Löwenberg, Bob, Thomas Pabst, Johan Maertens, Patrycja Gradowska, Bart J Biemond, Olivier Spertini, Edo Vellenga, et al. 2024. “Addition of Lenalidomide to Intensive Treatment in Younger and Middle-Aged Adults with Newly Diagnosed AML: The HOVON-SAKK-132 Trial.” Accessed September 15. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........f57abf9094f416349bbd7f9ecc75fc32&authtype=sso&custid=ns315887.